picture:
Title:
Ellen Verkallsteren, Postdoctoral Fellow
“We cannot translate this knowledge directly to humans, but we also cannot rule out that people with diabetes after stroke may have benefits if treated with SGLT-2 inhibitors,” says Elin Verkallsteren, a postdoctoral fellow at the Postdoctoral Institute. . Department of Clinical Research and Education, Södersjokhuset, Karolinska Institutet (KI SÖS) And the first author of the study.
The researchers now plan to go further and examine potential associations between different diabetes treatments and stroke outcomes in larger observational studies.
The study was created by Vladimir Darsalia and Cesar Patron V Neurocardiometabol group, Department of Clinical Research and Education, Södersjokhuset, and is the result of a collaboration with the Translational Neurology Group, Department of Clinical Sciences, Wallenberg Center for Neuroscience at Lund University, and Boehringer Ingelheim Pharma GmbH & Co. KG and Internal Medicine in Södersjukhuset.
The study was funded by the Heart Foundation, the Ulla Hamberg Angeby Foundation, the Lennart Angeby Foundation, the Swedish Research Council, STROKE-Riksförbundet, the ALF, and the Heart-Lung Foundation.
Publishing
The SGLT2 inhibitor Empagliflozin promotes functional recovery after stroke in diabetic miceElin Verkallesteren, Dimitra Karambatsi, Karolina Buesa, Thomas Nystrom, Thomas Klein, Jessen Pohl, Cesar Patron and Vladimir Daralia, Cardiovascular diseases, diabetes, Online 29 February 2024, doi: 10.1186/s12933-024-02174-6
More Stories
The contribution of virtual reality to research in medicine and health
The sun could hit the Internet on Earth
In memory of Jens Jørgen Jørgensen